Computational functional group mapping for drug discovery
SilcsBio, LLC Receives Phase II NIH SBIR Funding
FOR IMMEDIATE RELEASE: July 7, 2016 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Receives Phase II NIH SBIR Funding Baltimore, Maryland: SilcsBio, LLC announced today a $1.3 million funding award from the National Institute of Health to develop new computer aided drug design (CADD) software. CADD software enables pharmaceutical companies to […]
Ribosome-templated azide−alkyne cycloadditions: synthesis of potent macrolide antibiotics by in situ click chemistry
Structure-Based Design of N-Substituted 1-Hydroxy-4-sulfamoyl-2-naphthoates as Selective Inhibitors of the Mcl-1 Oncoprotein
SilcsBio Overview
Check out this video to understand more about SilcsBio!
SilcsBio Patent
SilcsBio has exclusive rights to use U.S. and foreign patents pending by the University of Maryland, Baltimore. Patents include: U.S. Patent Application 13/265,568, titled “Method for binding site identification by molecular dynamics simulation (SILCS: Site Identification by Ligand Competitive Saturation),” published as US 2012/0053067.
SILCS Drug Design Method
SILCS: Site Identification by Ligand Competitive Saturation is a ligand or drug design program that calculates the probability that general classes or specific R-groups will bind to a target molecule. This allows a medicinal chemist to design molecules that have a higher probability of binding the target protein. This method was developed by Dr. Alex […]